Study guide
7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead
Key Takeaways Explain This Topic AI
Universal screening for iron deficiency anemia (IDA) is mandated at 12 months of age with hemoglobin/hematocrit; oral repletion requires elemental iron 3 to 6 mg/kg/day with vitamin C, producing a reticulocytosis in 72 to 96 hours and a ≥1.0 g/dL hemoglobin rise within 4 weeks.
The CDC blood lead reference value (BLRV) is ≥3.5 µg/dL; blood lead levels of 45 to 69 µg/dL require oral chelation with succimer (DMSA), whereas levels ≥70 µg/dL or acute encephalopathy mandate PICU admission and dual parenteral chelation with IV CaNa2EDTA and IM dimercaprol (BAL), with BAL given 4 hours before EDTA to prevent worsening neurotoxicity.
Pediatric vision screening utilizes red reflex testing in infancy, instrument-based photoscreening at ages 1, 2, and 3 years, and optotype visual acuity charts starting at age 3 to 4 years (referral threshold: visual acuity worse than 20/50 at age 3, worse than 20/40 at age 4-5, or a ≥2-line interocular difference).
Universal adolescent health screening incorporates annual depression screening starting at age 12 (PHQ-9 modified for teens), universal lipid screening at ages 9 to 11 and 17 to 21, annual NAAT screening for Chlamydia and Gonorrhea in sexually active females, and universal one-time HIV testing between ages 15 and 18.
Minor consent laws grant mature adolescents legal authority to consent independently and confidentially for STI diagnosis/treatment, contraception, substance use treatment, and outpatient mental health without parental notification, with exceptions strictly limited to child abuse, acute suicidal intent, and homicidal threats.
Last updated: September 2026
Hematologic Screening: Iron Deficiency Anemia (IDA)
Iron deficiency is the most common single nutritional deficiency in childhood worldwide, peaking in incidence between 9 and 24 months of age . This vulnerability stems from rapid somatic growth, dramatic expansion of circulating erythrocyte volume, and the depletion of neonatal iron stores. Iron is an indispensable cofactor for oligodendrocyte maturation, myelin synthesis, and monoamine neurotransmitter production (dopamine, serotonin). Consequently, pediatric iron deficiency—even in the absence of overt anemia—causes permanent, irreversible impairments in neurocognitive development, attention, and executive function.
Universal vs. Selective Screening Mandates
Universal Screening : The American Academy of Pediatrics (AAP) Bright Futures guidelines recommend universal laboratory screening for iron deficiency anemia in all infants at 12 months of age using capillary or venous hemoglobin or hematocrit.
Selective High-Risk Screening : Selective screening is indicated earlier (at 4 to 6 months of age, or at any well-child check) in infants possessing major risk factors:
Prematurity (<37 weeks of gestation) or low birth weight (<2,500 g).
Maternal iron deficiency during pregnancy.
Consumption of unfortified cow's milk formula.
Early introduction of whole cow's milk before 12 months of age.
Excessive consumption of whole cow's milk (>24 oz [720 mL] per day) in toddlers.
Low socioeconomic status, poverty, or food insecurity.
Chronic blood loss (e.g., cow's milk protein enteropathy, gastrointestinal anomalies).
Infant Prophylaxis Guidelines
Term, Exclusively Breastfed Infants : Human breast milk contains highly bioavailable iron (50% absorbed vs. 10% in formula), but total iron concentration is low (0.3–0.5 mg/L). Neonatal hepatic iron stores become exhausted by 4 months. Exclusively or predominantly breastfed term infants must receive 1 mg/kg/day of oral elemental iron liquid drops beginning at 4 months of age , continuing until the infant regularly consumes adequate iron-rich complementary solid foods (iron-fortified infant cereals, pureed meats).
Preterm Infants (<37 Weeks) : Preterm infants miss the massive transplacental iron transfer that occurs during the third trimester. Preterm infants require 2 mg/kg/day of elemental iron starting by 1 month of chronological age , continuing through 12 months.
Laboratory Diagnosis & Differential Diagnosis
Diagnostic Profile of IDA :
Hemoglobin / Hematocrit: Low for age (at 12 months, anemia is defined as Hb <11.0 g/dL or Hct <33%).
Mean Corpuscular Volume (MCV): Decreased (microcytosis, MCV <70 fL).
Red Cell Distribution Width (RDW): Elevated (>15%) , reflecting marked anisocytosis (variable erythrocyte size).
Serum Ferritin: Decreased (<12 to 15 ng/mL) . Ferritin is the most sensitive and specific biomarker of total body iron stores. Clinical Caveat : Ferritin is an acute-phase reactant; systemic inflammation, viral infection, or fever can elevate ferritin into the normal range despite profound underlying iron deficiency.
Serum Iron: Decreased; Total Iron-Binding Capacity (TIBC): Elevated (>400 µg/dL) ; Transferrin Saturation: Low (<15%) .
Peripheral Blood Smear: Microcytic, hypochromic erythrocytes, anisocytosis, poikilocytosis, and pencil/cigar cells.
Distinguishing IDA from Thalassemia Minor :
Both cause microcytic anemia, but Beta-Thalassemia Minor typically features a normal RDW (<14%) , an elevated red blood cell count (RBC >5.0 million/µL) disproportionate to the degree of anemia, and target cells on peripheral smear.
Mentzer Index ( M C V / RBC count MCV / \text{RBC count} MC V / RBC count ): An index >13 strongly favors Iron Deficiency Anemia , whereas an index <13 favors Thalassemia Trait .
Treatment and Response Monitoring
Therapeutic Regimen : Oral elemental iron at 3 to 6 mg/kg/day (typically 3 mg/kg/day for mild-to-moderate, up to 6 mg/kg/day for severe anemia) divided into 1 to 2 daily doses (e.g., ferrous sulfate elixir or drops containing 15 mg elemental iron per 1 mL).
Administration Instructions : Administer between meals or on an empty stomach with water or a rich source of vitamin C (ascorbic acid) , such as citrus juice, which reduces ferric iron (Fe3+) to the soluble ferrous state (Fe2+), dramatically enhancing absorption across the duodenal mucosa. Avoid administering iron concurrently with cow's milk, infant formula, or calcium , which bind iron and severely inhibit absorption. Counsel parents regarding expected benign dark black or green stools and temporary, reversible teeth staining (can be minimized by placing drops at the back of the tongue or brushing teeth post-administration).
Dietary Modification : Limit whole cow's milk consumption to no more than 16 to 24 oz (480 to 720 mL) per day . Excessive milk consumption drives anemia through a dual mechanism: inducing microscopic occult intestinal mucosal blood loss from bovine protein enteropathy, and creating satiety that displaces iron-dense solid foods ("milk anemia").
Timeline of Hematologic Response :
Subjective Improvement : Within 24 to 48 hours , irritability decreases and appetite improves due to rapid replenishment of iron-dependent intracellular neuronal enzymes.
Reticulocyte Response : Bone marrow reticulocytosis begins within 72 hours and peaks at 7 to 10 days (confirming adherence and correct diagnosis).
Hemoglobin Rise : Hemoglobin increases by ≥1.0 g/dL within 4 weeks . A follow-up CBC must be checked at 4 weeks.
Duration of Therapy : Once hemoglobin normalizes, continue oral iron therapy for an additional 2 to 3 months to fully replenish depleted hepatic and reticuloendothelial iron stores (ferritin).
Childhood Blood Lead Screening & Toxic Exposure Management
Lead is a pervasive, cumulative environmental neurotoxin with no safe blood lead level in children . Lead readily crosses the blood-brain barrier via divalent cation transporters, substituting for calcium and zinc in cellular signaling pathways. It disrupts synaptogenesis, induces neuronal apoptosis, and impairs monoaminergic neurotransmission. Even low-level lead exposure produces irreversible neurocognitive damage: IQ loss, executive dysfunction, shortened attention span, school failure, and impulse control disorders.
Environmental Risk Factors
Deteriorated Lead-Based Paint : The predominant source in the US. Homes built prior to 1978 (and especially prior to 1950) containing peeling, cracking, or chipped paint, or contaminated lead dust generated during renovations or from sliding windows and doors.
Plumbing and Water : Lead service lines, lead pipes, and brass plumbing fixtures joined with lead solder.
Imported Products : Glazed ceramic cookware and terra cotta pottery (lead glazes leach into acidic foods), imported candies, foreign spices (turmeric, chili powder adulterated with lead chromate), and antique pewter toys.
Traditional Folk Remedies : Traditional remedies such as Greta and Azarcon (bright orange-yellow powders containing up to 90% lead tetroxide used in Hispanic cultures for gastrointestinal upset/colic), Pay-loo-ah (used in Southeast Asian cultures for fever), and Kohl, Kajal, or Surma (lead-containing cosmetic eye powders used in South Asian and Middle Eastern cultures).
Occupational / Take-Home Exposures : Battery recycling/manufacturing, construction, demolition, radiator repair, scrap metal smelting, lead fishing sinker casting, and indoor firearms ranges.
Screening Protocols & Blood Lead Reference Value
Universal Screening : Universal blood lead testing is mandated at 12 months and 24 months of age for:
All children enrolled in Medicaid or the Children's Health Insurance Program (CHIP).
Children living in high-risk geographic areas (defined by state/local health departments as communities where ≥27% of housing was built prior to 1950 or where lead exposure prevalence is ≥12%).
Immigrant, refugee, and internationally adopted children upon arrival in the US.
Selective Screening : Administer an environmental risk questionnaire at every well-child visit from 6 months to 6 years of age; perform blood lead testing if any question is answered affirmatively.
Capillary vs. Venous Confirmation : Capillary (fingerstick) testing is a convenient screening tool but is subject to high false-positive rates due to environmental lead dust on the child's skin. Any elevated capillary blood lead level MUST be confirmed with a venous blood draw before initiating clinical interventions or chelation.
CDC Blood Lead Reference Value (BLRV) : Updated to ≥3.5 µg/dL (established from the 97.5th percentile of the National Health and Nutrition Examination Survey [NHANES] blood lead distribution in US children aged 1 to 5 years).
Staged Clinical Management by Confirmed Venous Blood Lead Level (BLL)
Venous Blood Lead Level Clinical Stage Required Action & Therapeutic Management
<3.5 µg/dL Normal Reference Provide standard anticipatory guidance regarding environmental hazards and nutrition. Rescreen at 24 months if indicated.
3.5 to 19 µg/dL Mild Elevation (≥BLRV) • Provide parent education regarding lead sources, handwashing, and wet-cleaning of window sills.; • Perform an environmental risk assessment to identify and eliminate exposure.; • Nutritional Counseling : Ensure adequate dietary intake of calcium, iron, and vitamin C (calcium and iron competitively inhibit lead absorption at the intestinal divalent metal transporter-1 [DMT-1]; vitamin C promotes lead excretion).; • Developmental surveillance.; • Repeat venous BLL in 1 to 3 months (within 1 month if <12 months old or rising).
20 to 44 µg/dL Moderate Elevation • All measures above, PLUS:; • Coordinate with the local public health department for a formal home environmental lead investigation and certified abatement .; • Perform an abdominal radiograph if acute ingestion of paint chips or lead foreign bodies is suspected.; • If radio-opaque paint flakes are visible on radiograph, initiate bowel decontamination with polyethylene glycol (whole bowel irrigation) .; • Repeat venous BLL within 1 month ; chelation is generally not indicated unless levels persist near 45 µg/dL.
45 to 69 µg/dL Severe Elevation (Chelation Indicated) • Oral Chelation Therapy is indicated with Succimer (dimercaptosuccinic acid, DMSA) .; • Dosing : 10 mg/kg (or 350 mg/m²) orally three times daily for 5 days, followed by 10 mg/kg orally twice daily for 14 days (total 19-day course ).; • Hospitalize if the home environment cannot be immediately guaranteed to be lead-free, because chelators increase lead absorption if ongoing exposure occurs.; • Monitor complete blood count (risk of neutropenia ) and liver transaminases.; • Repeat venous BLL 7 to 14 days post-chelation to evaluate for rebound due to bone redistribution.
≥70 µg/dL OR Acute Encephalopathy Critical Medical Emergency • Immediate PICU Admission .; • Presents with acute lead encephalopathy: projectile vomiting, ataxia, altered mental status, papilledema, seizures, or coma.; • Dual Parenteral Chelation Therapy : Intravenous Calcium Disodium Versenate (CaNa2EDTA) PLUS Intramuscular Dimercaprol (British Anti-Lewisite, BAL) .; • CRITICAL PROTOCOL (BAL BEFORE EDTA) : BAL must be administered at least 4 hours BEFORE the first dose of CaNa2EDTA .; • Maintain generous intravenous hydration and verify adequate urine output prior to starting EDTA (prevents renal tubular necrosis).
The Life-Saving Mechanism: BAL Administered 4 Hours Before EDTA
The biochemical rationale for administering Dimercaprol (BAL) prior to Calcium Disodium EDTA is a quintessential ABFM board exam concept. Dimercaprol is a lipophilic, non-ionized dithiol compound that readily crosses cell membranes and the blood-brain barrier, chelating intracellular lead and clearing it into the bile. In contrast, CaNa2EDTA is hydrophilic and restricted strictly to the extracellular compartment. If CaNa2EDTA is administered alone or prior to BAL, it mobilizes large reservoirs of lead from bone and soft tissues into the systemic circulation; this mobilized unbound lead then crosses the compromised blood-brain barrier into cerebral tissue, precipitating or aggravating fatal cerebral edema and acute lead encephalopathy . Therefore, BAL must always lead EDTA by at least 4 hours.
Pediatric Vision & Hearing Screening Protocols
Sensory impairments during early childhood disrupt neural pathway development in the visual and auditory cortex, leading to permanent functional deficits (amblyopia, permanent language delay) if not identified and treated within critical sensitive windows.
Pediatric Vision Screening Schedule & Diagnostic Modalities
Newborn to 12 Months: Red Reflex & Fixation :
Red Reflex (Bruckner Test) : Assessed at every well-child check in a darkened room using a direct ophthalmoscope. Any asymmetric reflex, dark spot, or leukocoria (white pupillary reflex) mandates urgent same-day referral to pediatric ophthalmology to evaluate for retinoblastoma, congenital cataract, or retinal detachment.
Fixation and Tracking : Full-term infants fixate on faces shortly after birth. By 2 to 3 months of age , infants must demonstrate steady fixation and smooth pursuit tracking of objects past the midline (180°). Inability to fixate and track by 3 months warrants urgent ophthalmologic and neurologic evaluation.
Ocular Alignment & Strabismus :
Evaluated using the Corneal Light Reflex (Hirschberg Test) and the Cover/Uncover Test . When directing a light at the eyes from 2 feet away, symmetrical pinpoint light reflections located slightly nasal to the center of each pupil are normal.
Physiological Laxity vs. Strabismus : Intermittent ocular misalignment is physiologically normal up to 4 to 6 months of age . However, any persistent, fixed strabismus at ANY age , or any intermittent strabismus persisting beyond 4 to 6 months of age , is distinctly pathologic.
Risk of Amblyopia : Strabismus (esotropia [inward], exotropia [outward]) or severe anisometropia causes the visual cortex to actively suppress the blurred image from the misaligned eye, leading to irreversible loss of visual acuity ( amblyopia or "lazy eye"). Treatment involves optical correction, occlusion therapy (patching the sound eye), or surgical realignment before age 7 to 8 years.
Instrument-Based Photoscreening (Ages 1, 2, and 3 Years) :
The AAP recommends automated instrument-based vision screening (photoscreeners or handheld autorefractors) at 12, 24, and 36 months of age (and annually until optotype acuity charts can be reliably completed). Automated cameras capture pupillary reflexes to detect amblyogenic risk factors: high hyperopia, significant myopia, astigmatism, anisometropia (refractive asymmetry between eyes), and strabismus.
Subjective Visual Acuity Chart Screening (Starting at Age 3 to 4 Years) :
Formal optotype chart testing begins at age 3 to 4 years using standardized recognition charts: Lea Symbols (apple, house, circle, square) or HOTV charts with matching cards, progressing to Tumbling E or Snellen charts for older children.
Ophthalmology Referral Thresholds :
Age 3 Years : Visual acuity worse than 20/50 in either eye.
Ages 4 to 5 Years : Visual acuity worse than 20/40 in either eye.
Ages ≥6 Years : Visual acuity worse than 20/30 in either eye.
Interocular Discrepancy : A difference of ≥2 lines of visual acuity between eyes at any age (e.g., 20/25 in the right eye and 20/40 in the left eye) warrants immediate referral, as anisometropic amblyopia is highly probable.
Pediatric Hearing Screening Protocols
Universal Newborn Hearing Screening (The EHDI 1-3-6 Rule) :
Screened prior to discharge or by 1 month of age using Automated Auditory Brainstem Response (AABR) or Otoacoustic Emissions (OAE).
If the screen is failed, complete a diagnostic audiologic evaluation by 3 months of age .
If permanent hearing loss is confirmed, initiate early intervention services (auditory amplification, speech therapy) by 6 months of age .
High-Risk Indicators for Delayed-Onset / Progressive Sensorineural Hearing Loss :
Even if the newborn screen is passed, children with high-risk factors require repeat formal audiologic surveillance between 24 and 30 months of age :
Congenital cytomegalovirus (CMV) infection (the most common non-genetic cause of childhood sensorineural hearing loss), congenital toxoplasmosis, syphilis, or rubella.
Bacterial or fungal meningitis.
Severe neonatal hyperbilirubinemia requiring exchange transfusion.
Prolonged NICU admission (>5 days), ECMO, or assisted mechanical ventilation.
Exposure to ototoxic medications (systemic aminoglycosides [gentamicin], loop diuretics [furosemide]).
Craniofacial malformations (microtia, cleft palate, temporal bone anomalies).
Family history of hereditary permanent childhood hearing loss.
School-Age Pure-Tone Audiometry Screening :
Formal subjective pure-tone audiometry is recommended at well-child visits at ages 4, 5, 6, 8, and 10 years , and once during early adolescence (11 to 14 years), mid-adolescence (15 to 17 years), and late adolescence (18 to 21 years).
Frequencies Tested : Pure tones tested at 1000, 2000, and 4000 Hz at an intensity threshold of 20 dB HL (Hearing Level) in each ear individually.
Referral Criteria : Failure to respond to any single frequency in either ear constitutes a failed screen, mandating pneumatic otoscopy (to exclude middle ear effusion / otitis media with effusion) and referral to a pediatric audiologist.
Adolescent Health Surveillance, Lipid/Depression/STI Screening & Confidentiality
Adolescence (ages 11 to 21 years) is characterized by profound neurodevelopmental remodeling, identity formation, and exploration. Providing high-quality adolescent healthcare requires family physicians to balance parental engagement with strict legal and ethical confidentiality protections.
Universal Adolescent Screening Mandates
Depression Screening :
Universal annual screening for Major Depressive Disorder (MDD) is mandated for all adolescents starting at age 12 through 21 years (AAP and USPSTF Grade B recommendation).
Screening utilizes validated instruments: the Patient Health Questionnaire-9 modified for Adolescents (PHQ-9A / PHQ-9M) or the two-item PHQ-2.
Any endorsement of item 9 (suicidal ideation) mandates an immediate in-clinic safety risk assessment , lethal means restriction counseling (securing household firearms and locking up medications), and emergency psychiatric crisis intervention if active intent or plan is present.
Lipid Screening :
The National Heart, Lung, and Blood Institute (NHLBI) and the AAP mandate universal pediatric lipid screening twice during youth:
First Screen : Once between ages 9 and 11 years (prior to the onset of puberty, when physiological lipid shifts occur).
Second Screen : Once between ages 17 and 21 years .
Modality: Non-fasting non-HDL cholesterol ( N o n - H D L = Total Cholesterol − HDL Non\text{-}HDL = \text{Total Cholesterol} - \text{HDL} N o n - HD L = Total Cholesterol − HDL ) or a fasting lipid panel. Targeted screening is indicated outside these windows for children with family history of premature cardiovascular disease (myocardial infarction, stent, or stroke in a parent/grandparent <55y in males, <65y in females) or dyslipidemia.
Sexually Transmitted Infection (STI) Screening :
Chlamydia & Gonorrhea : Annual universal screening using urine Nucleic Acid Amplification Testing (NAAT) is recommended for all sexually active females aged <25 years, and for sexually active males reporting high-risk behaviors (multiple partners, inconsistent condom use, men who have sex with men [MSM]).
HIV Screening : Universal opt-out screening for HIV infection at least once between ages 15 and 18 years using a 4th-generation HIV-1/2 antigen/antibody immunoassay, regardless of reported sexual activity.
Cervical Cancer Screening : Routine cervical cancer screening (Pap smear / HPV testing) is NOT recommended before age 21 , regardless of the age of sexual debut, because transient HPV infections in adolescents clear spontaneously without progressing to invasive carcinoma, while cervical procedures increase risks of future cervical incompetence.
Confidential Adolescent Care & Minor Consent Laws
Adolescents consistently identify confidentiality concerns as the single greatest barrier to seeking healthcare for sensitive conditions. When confidentiality is guaranteed, adolescents are significantly more likely to disclose sexual activity, depression, substance use, and abuse.
Dedicated Confidential Time : Starting at age 11 to 12 years , the family physician should explain the practice's confidentiality policy jointly to the parent and adolescent, and then routinely excuse parents from the exam room for a dedicated portion of every encounter .
Legal Minor Consent Rights :
In virtually all 50 US states and territories, statutes explicitly grant mature minors the legal right to provide independent, confidential consent— without parental notification or parental consent —for the following categories of healthcare:
Sexually Transmitted Infections (STIs) : Testing, diagnosis, counseling, and medical treatment (including expedited partner therapy).
Contraceptive Services : Prescription oral contraceptives, intrauterine devices (IUDs), subdermal etonogestrel implants, injectable depot medroxyprogesterone acetate, and emergency contraception.
Pregnancy Care & Prenatal Care : Prenatal care and pregnancy testing (note: abortion consent laws vary widely by state, with some states requiring parental notification or judicial bypass).
Substance Use Disorder (SUD) Services : Outpatient medical evaluation, counseling, and addiction treatment.
Outpatient Mental Health Care : Outpatient mental health counseling and crisis evaluation (many states establish explicit age thresholds, commonly age 12, 14, or 16 years, permitting independent consent).
Mandatory Limits of Confidentiality (When to Breach)
Physicians must explicitly counsel adolescents at the outset regarding the three specific, non-negotiable legal and ethical exceptions where confidentiality MUST be breached to ensure patient safety:
Suspected Child Abuse or Neglect : Physical abuse, sexual abuse, emotional abuse, or severe neglect involving a minor. The physician is a mandated reporter and must report immediately to Child Protective Services (CPS) or law enforcement.
Imminent Risk of Severe Self-Harm (Suicide) : Active suicidal ideation with specific intent, plan, or suicide attempt. Requires acute crisis stabilization, safety planning, psychiatric evaluation, and parental notification.
Imminent Risk of Severe Physical Harm to Others (Homicide) : Threats of violence toward an identifiable individual, triggering the legal duty to protect and warn (Tarasoff doctrine).
Exam Strategy : Except for these three explicit scenarios (abuse, active suicide, homicide), adolescent confidentiality must be fiercely defended. If a parent demands access to an adolescent's STI test results, pregnancy test, or birth control records, the family physician must refuse disclosure, explain that the minor's consent is legally protected, and encourage the adolescent to engage in open communication with the family when safe to do so.